Nautilus Biotechnology, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Nautilus Biotechnology, Inc. (NAUT) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $2.15 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-07-28
- Nautilus Biotechnology, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $1.01M, a 13.95% decline year-over-year.
- Nautilus Biotechnology, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $1.14M, a 1.55% decline year-over-year.
- Nautilus Biotechnology, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $1.18M, a 5.53% increase year-over-year.
- Nautilus Biotechnology, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $1.19M, a 8.75% increase year-over-year.
- Nautilus Biotechnology, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $4.71M, a 7.63% increase from fiscal 2024.
- Nautilus Biotechnology, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $4.38M, a 13.54% increase from fiscal 2023.
- Nautilus Biotechnology, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $3.86M, a 75.35% increase from fiscal 2022.
- Nautilus Biotechnology, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $2.20M, a 20.63% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 1 month | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-28 | $2.15M 10-Q · filed 2026-07-28 | $3.34M derived: sum of 3 quarters · filed 2026-07-28 | $4.53M derived: sum of 4 quarters · filed 2026-07-28 | |
| 2026-03-31 | $1.14M 10-Q · filed 2026-04-28 | $2.33M derived: sum of 2 quarters · filed 2026-04-28 | $3.52M derived: sum of 3 quarters · filed 2026-04-28 | $4.69M derived: sum of 4 quarters · filed 2026-07-28 | |
| 2025-12-31 | $4.20M 10-K · filed 2026-02-26 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.38M derived: sum of 2 quarters · filed 2026-02-26 | $3.55M derived: sum of 3 quarters · filed 2026-07-28 | $4.71M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $2.37M derived: sum of 2 quarters · filed 2026-07-28 | $3.53M 10-Q · filed 2025-10-28 | $4.65M derived: sum of 4 quarters · filed 2026-07-28 | |
| 2025-06-30 | $1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-28 | $2.34M 10-Q · filed 2026-07-28 | $3.46M derived: sum of 3 quarters · filed 2026-07-28 | $4.55M derived: sum of 4 quarters · filed 2026-07-28 | |
| 2025-03-31 | $1.16M 10-Q · filed 2026-04-28 | $2.28M derived: sum of 2 quarters · filed 2026-04-28 | $3.38M derived: sum of 3 quarters · filed 2026-04-28 | $4.46M derived: sum of 4 quarters · filed 2026-04-28 | |
| 2024-12-31 | $1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.22M derived: sum of 2 quarters · filed 2026-02-26 | $3.30M derived: sum of 3 quarters · filed 2026-02-26 | $4.38M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $2.18M derived: sum of 2 quarters · filed 2025-10-28 | $3.26M 10-Q · filed 2025-10-28 | $4.29M derived: sum of 4 quarters · filed 2025-10-28 | |
| 2024-06-30 | $1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $2.16M 10-Q · filed 2025-07-31 | $3.19M derived: sum of 3 quarters · filed 2025-07-31 | $4.21M derived: sum of 4 quarters · filed 2025-07-31 | |
| 2024-03-31 | $1.07M 10-Q · filed 2025-04-29 | $2.11M derived: sum of 2 quarters · filed 2025-04-29 | $3.13M derived: sum of 3 quarters · filed 2025-04-29 | $4.14M derived: sum of 4 quarters · filed 2025-04-29 | |
| 2023-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.05M derived: sum of 2 quarters · filed 2025-02-27 | $3.07M derived: sum of 3 quarters · filed 2025-02-27 | $3.86M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $1.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | $2.04M derived: sum of 2 quarters · filed 2024-10-29 | $2.82M 10-Q · filed 2024-10-29 | $3.40M derived: sum of 4 quarters · filed 2024-10-29 | |
| 2023-06-30 | $1.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | $1.81M 10-Q · filed 2024-07-30 | $2.38M derived: sum of 3 quarters · filed 2024-07-30 | $2.93M derived: sum of 4 quarters · filed 2024-07-30 | |
| 2023-03-31 | $786.00K 10-Q · filed 2024-04-30 | $1.36M derived: sum of 2 quarters · filed 2024-04-30 | $1.91M derived: sum of 3 quarters · filed 2024-04-30 | $2.46M derived: sum of 4 quarters · filed 2024-04-30 | |
| 2022-12-31 | $575.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $1.13M derived: sum of 2 quarters · filed 2024-02-28 | $1.67M derived: sum of 3 quarters · filed 2024-02-28 | $2.20M 10-K · filed 2024-02-28 | |
| 2022-09-30 | $551.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $1.10M derived: sum of 2 quarters · filed 2023-10-31 | $1.62M 10-Q · filed 2023-10-31 | $2.23M derived: sum of 4 quarters · filed 2023-10-31 | |
| 2022-06-30 | $548.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $1.07M 10-Q · filed 2023-08-02 | $1.68M derived: sum of 3 quarters · filed 2023-08-02 | $2.14M derived: sum of 4 quarters · filed 2023-08-02 | |
| 2022-03-31 | $525.00K 10-Q · filed 2023-05-02 | $1.13M derived: sum of 2 quarters · filed 2023-05-02 | $1.59M derived: sum of 3 quarters · filed 2023-05-02 | $1.94M derived: sum of 4 quarters · filed 2023-05-02 | |
| 2021-12-31 | $606.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $1.06M derived: sum of 2 quarters · filed 2023-02-23 | $1.41M derived: sum of 3 quarters · filed 2023-02-23 | $1.82M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $457.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $804.00K derived: sum of 2 quarters · filed 2022-11-01 | $1.22M 10-Q · filed 2022-11-01 | $1.62M derived: sum of 4 quarters · filed 2022-11-01 | |
| 2021-06-30 | $347.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $760.00K 10-Q · filed 2022-08-02 | $1.16M derived: sum of 3 quarters · filed 2022-08-02 | $1.56M derived: sum of 4 quarters · filed 2022-08-02 | |
| 2021-03-31 | $413.00K 10-Q · filed 2022-05-03 | $817.00K derived: sum of 2 quarters · filed 2022-05-03 | $1.21M derived: sum of 3 quarters · filed 2022-05-03 | ||
| 2020-12-31 | $404.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $800.00K derived: sum of 2 quarters · filed 2022-02-24 | $1.64M 10-K · filed 2022-02-24 | ||
| 2020-09-30 | $396.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $1.23M 10-Q · filed 2021-11-02 | |||
| 2020-06-30 | $836.00K 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |